From: Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Combination therapy | Type of cancer | Phase | N | Outcome (most relevant findings) | Literature |
---|---|---|---|---|---|
None | Relapsed/refractory Hodgkin lymphoma | II | 53 | 1CR, 10PR, 31SD | Younes et al. (2009)a |
None | Myelofibrosis (MF) | I | 176 (thereof n = 13 with MF) | MF:1PR, 3CI | DeAngelo et al. (2009)a |
None | Myelofibrosis | I | 8 | 2CI; 4SD | Mascarenhas et al. (2009)a |
Lenalidomid, Dexamethasone | Multiple myeloma | I | 22 | 5/10Â mg Panobinostat: regarded as safe | Spencer et al. (2009)a |
Bortezomib | Relapsed multiple myeloma | I | 28 | 64% Response: 4CR; 10PR; 4 minor responses | San-Miguel et al. (2009)a |
Melphalan | Multiple myeloma | I | 12 | 1CR; 3PR; 4SD | |
Imatinib | Chronic myeloic leukemia | I | n = 5 | MTD to be determined | Bhatia et al. (2009)a |
Docetaxel | Castration-resistant prostate cancer | I | n = 16 | no effects as single agents; 5 patients with PSA decline >50% | Rathkopf et al. (2010) |
Trastuzumab | HER-2 positive metastatic breast cancer | I | n = 18 |  | Conte et al. (2009) |